CIBC Asset Management’s Amneal Pharmaceuticals AMRX Stock Holding History

CIBC Asset Management’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$245K	Sell	14,125 -130	-0.9%	-$1.78K	﹤0.01%	1180
2026 Q1	$177K	Buy	+14,255	New	+$191K	﹤0.01%	1252
2022 Q4	–	Sell	-14,567	Closed	-$29K	–	1071
2022 Q3	$29K	Hold	14,567	–	–	﹤0.01%	1228
2022 Q2	$46K	Sell	14,567 -1,066	-7%	-$3.86K	﹤0.01%	1236
2022 Q1	$65K	Hold	15,633	–	–	﹤0.01%	1481
2021 Q4	$75K	Buy	15,633 +1,395	+10%	+$6.96K	﹤0.01%	1504
2021 Q3	$76K	Buy	14,238 +2,024	+17%	+$10.2K	﹤0.01%	1435
2021 Q2	$63K	Hold	12,214	–	–	﹤0.01%	1354
2021 Q1	$82K	Sell	12,214 -52	-0.4%	-$288	﹤0.01%	1310
2020 Q4	$56K	Hold	12,266	–	–	﹤0.01%	1228
2020 Q3	$48K	Buy	12,266 +304	+3%	+$1.3K	﹤0.01%	1103
2020 Q2	$57K	Hold	11,962	–	–	﹤0.01%	1060
2020 Q1	$42K	Hold	11,962	–	–	﹤0.01%	980
2019 Q4	$58K	Buy	+11,962	New	+$41.6K	﹤0.01%	1164

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

CIBC Asset Management's AMRX Position: Q2 2026 in Review

CIBC Asset Management reduced its Amneal Pharmaceuticals (AMRX) stake by 0.91% in Q2 2026, selling an estimated $1.78K and leaving 14,125 shares worth $245K. The position accounts for ﹤0.01% of the portfolio, ranked #1180.

CIBC Asset Management first reported a position in AMRX in Q4 2019 and has held it in 14 quarters since. 310 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

CIBC Asset Management held 14,125 shares of Amneal Pharmaceuticals worth $245K as of Q2 2026.
CIBC Asset Management sold 130 Amneal Pharmaceuticals shares in Q2 2026, an estimated $1.78K.
Amneal Pharmaceuticals made up ﹤0.01% of CIBC Asset Management's portfolio in Q2 2026, its #1180 holding.
CIBC Asset Management first reported a position in Amneal Pharmaceuticals in Q4 2019 and has held it in 14 quarters since.
310 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on CIBC Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.